These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21054456)

  • 21. Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
    Kast RE; Ramiro S; Lladó S; Toro S; Coveñas R; Muñoz M
    J Neurooncol; 2016 Feb; 126(3):425-31. PubMed ID: 26603162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with CCR5 antagonists: which patient may have a benefit?
    Mueller MC; Bogner JR
    Eur J Med Res; 2007 Oct; 12(9):441-52. PubMed ID: 17933726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
    Prommer E
    J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
    Meanwell NA; Kadow JF
    Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA advisory committee approves Selzentry.
    AIDS Patient Care STDS; 2009 Nov; 23(11):987. PubMed ID: 19938371
    [No Abstract]   [Full Text] [Related]  

  • 28. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
    van Lunzen J
    Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
    Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
    J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in HIV-1 tropism: clinical and prognostic consequences.
    Mosier DE
    Eur J Med Res; 2007 Oct; 12(9):371-4. PubMed ID: 17933716
    [No Abstract]   [Full Text] [Related]  

  • 35. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
    Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug safety evaluation of maraviroc for the treatment of HIV infection.
    Wasmuth JC; Rockstroh JK; Hardy WD
    Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.
    Kast RE
    Clin Transl Oncol; 2009 Jul; 11(7):408-10. PubMed ID: 19574198
    [No Abstract]   [Full Text] [Related]  

  • 39. CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1.
    Lorenzen T; Stoehr A; Walther I; Plettenberg A
    Eur J Med Res; 2007 Oct; 12(9):419-25. PubMed ID: 17933723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First medication in new class of ARTs poised to be available for salvage therapy. Tropism testing helps determine best patients for drug.
    AIDS Alert; 2007 Aug; 22(8):85-8. PubMed ID: 17763555
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.